| (Values in U.S. Thousands) | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 | Mar, 2020 |
| Sales | 629,180 | 572,950 | 561,350 | 548,970 | 644,770 |
| Sales Growth | +9.81% | +2.07% | +2.26% | -14.86% | -3.75% |
| Net Income | 53,870 | 25,450 | 58,270 | -386,650 | 244,240 |
| Net Income Growth | +111.67% | -56.32% | +115.07% | -258.31% | -13.32% |
Taro Pharm Inds (TARO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals.
Fiscal Year End Date: 03/31